quinazolines has been researched along with Cognition Disorders in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chou, CH; Yang, CR | 1 |
| Chen, R; Hei, Y; Liu, W; Long, Q; Mao, X; Wang, J | 1 |
| Aisner, DL; Berge, EM; Damek, D; Doebele, RC; Poonia, S | 1 |
| Gil, C; Lipina, TV; Martinez, A; Palomo, V; Roder, JC | 1 |
| Appenroth, D; Decker, M; Fleck, C; Lehmann, J; Mohr, K; Tränkle, C | 1 |
5 other study(ies) available for quinazolines and Cognition Disorders
| Article | Year |
|---|---|
Neuroprotective Studies of Evodiamine in an Okadaic Acid-Induced Neurotoxicity.
Topics: Alzheimer Disease; Animals; Apoptosis; Brain; Cell Line; Cognition; Cognition Disorders; Disease Models, Animal; Humans; Male; Maze Learning; Mice; Mice, Inbred ICR; Neurodegenerative Diseases; Neurons; Neuroprotection; Neuroprotective Agents; Okadaic Acid; Phosphorylation; Quinazolines; Spatial Memory; tau Proteins; Tauopathies | 2021 |
Neuregulin1 attenuates cognitive deficits and hippocampal CA1 neuronal apoptosis partly via ErbB4 receptor in a rat model of chronic cerebral hypoperfusion.
Topics: Animals; Apoptosis; Brain Ischemia; Cognition; Cognition Disorders; Cognitive Dysfunction; Disease Models, Animal; Hippocampus; Male; Maze Learning; Memory; Neuregulin-1; Neurons; Neuroprotective Agents; Quinazolines; Rats; Rats, Sprague-Dawley; Receptor, ErbB-4; Spatial Learning; Temporal Lobe; Tyrphostins | 2019 |
EGFR exon 19 deletion mutations and systemic/central nervous system miliary metastasis: clinical correlations and response to therapy.
Topics: Carcinoma, Non-Small-Cell Lung; Cognition Disorders; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Exons; Humans; Lung Neoplasms; Male; Meningeal Carcinomatosis; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Sequence Deletion; Treatment Outcome | 2014 |
Dual inhibitor of PDE7 and GSK-3-VP1.15 acts as antipsychotic and cognitive enhancer in C57BL/6J mice.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Cognition Disorders; Cyclic Nucleotide Phosphodiesterases, Type 7; Dose-Response Relationship, Drug; Drugs, Investigational; Enzyme Inhibitors; Glycogen Synthase Kinase 3; Male; Memory; Mice; Mice, Inbred C57BL; Molecular Targeted Therapy; Neural Inhibition; Nootropic Agents; Phosphodiesterase Inhibitors; Quinazolines; Schizophrenia; Spatial Behavior; Triazoles | 2013 |
In vivo investigations on the cholinesterase-inhibiting effects of tricyclic quinazolinimines: scopolamine-induced cognitive impairments in rats are attenuated at low dosage and reinforced at higher dosage.
Topics: Allosteric Regulation; Animals; Azocines; Cholinergic Antagonists; Cholinesterase Inhibitors; Cognition; Cognition Disorders; Dose-Response Relationship, Drug; Drug Interactions; Female; Imines; Maze Learning; Memory, Short-Term; Quinazolines; Rats; Rats, Wistar; Scopolamine; Tritium | 2008 |